PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.52%
Revenue growth of 4.52% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
4.09%
Gross profit growth of 4.09% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-0.99%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-1.75%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
23.00%
Net income growth of 23.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
22.99%
EPS growth of 22.99% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
22.99%
Diluted EPS growth of 22.99% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.07%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.06%. Joel Greenblatt would see a meaningful advantage if shares are undervalued.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
150.12%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 56.32%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
55.30%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 19.44%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
35.06%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 10.58%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
182.20%
Net income/share CAGR of 182.20% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
18.63%
5Y net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would check that top-line growth and share count management both contribute.
27.20%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 6.21%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
325.14%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 41.60% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
83.13%
5Y equity/share CAGR of 83.13% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
35.58%
3Y equity/share CAGR of 35.58% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
100.00%
Dividend/share CAGR of 100.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
118.18%
5Y dividend/share CAGR of 118.18% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
118.18%
3Y dividend/share CAGR of 118.18% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
12.35%
AR growth of 12.35% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
4.44%
Inventory growth of 4.44% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
10.86%
Asset growth of 10.86% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.19%
BV/share growth of 3.19% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
218.26%
Debt growth of 218.26% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
5.27%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.